Efficacy of once every four week oral minodronate in patients with glucocorticoid-induced osteoporosis after switching from weekly oral bisphosphonate

Efficacy of once every four week oral minodronate in patients with glucocorticoid-induced osteoporosis after switching from weekly oral bisphosphonate - Efficacy of once every four week oral minodronate in patients with glucocorticoid-induced osteoporosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013305

Enrollment

160

Registered

2014-02-28

Start date

2013-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucocorticoid-induced osteoporosis

Interventions

Minodronate 50mg tablet (once every 4 weeks) Weekly bisphosphonate tablet (alendronate 35 mg or risedronate 17.5 mg tablet)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pateints with following rheumatic disease or connective tissue disease, such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, dermatomyositis, polymyositis, Sjogren's syndrome, mixed connective tissue disease, vasculitis syndrome, Behcet disease, and polymyalgoa rheumatica. 2) Patients who has been treated with corticosteroid at average dose more than 5 mg/day prednisolone equivalent for the last 3 months. 3) Patients who has been treated with weekly oral bisphosphonate, such as alentronate or risedronate.

Exclusion criteria

Exclusion criteria: 1) Patients with esophageal dysmortility, such as esophageal constriction or achalasia. 2) Patients who could not stay upright position after taking medicine. 3) Patients who had allergic reaction to bisphosphonate. 4) Patients with hypocalcemia. 5) Patients who is presently breast-feeding, is pregnant, is suspected to be pregnant, or cannot use birth control during the study period. 6) Patients who are receiving bisphosphonate other than oral weekly bisphosphonate, teriparatide, or denosumab. 7) Patients who are planning to receive dental extraction in the enrollment period.

Design outcomes

Primary

Measure	Time frame
Patients' satisfaction regarding medication at the week 24 and the week 52 after random allocation	—

Secondary

Measure	Time frame
Changes in bone mineral density and bone metabolic markers at the week 24 and the week 52 after random allocation	—

Countries

Japan

Contacts

Public ContactTaio Naniwa

Nagoya City University Hospital Division of Rheumatology, Department of Internal Medicine

tnaniwa@med.nagoya-cu.ac.jp0528538216

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026